Windlas Biotech (NSE:WINDLAS) ROCE %: 14.76% (As of Mar. 2026)


NSE:WINDLAS Windlas Biotech Ltd NSE:WINDLAS
89 GF Score
Price ₹863.80
GF Value ₹936.76
Valuation Fairly Valued
! 1 Warning Sign
View Full Analysis

What is Windlas Biotech ROCE %?

Windlas Biotech NSE:WINDLAS +0.94% 89 ROCE % is 14.76% as of Mar. 2026. GuruFocus rates NSE:WINDLAS with a GF Score™ of 89/100 and a GF Value™ of ₹936.76 (Fairly Valued). The stock has 1 warning sign investors should review.

ROCE % measures how well a company generates profits from its capital. It is calculated as EBIT divided by Capital Employed, where Capital Employed is calculated as Total Assets minus Total Current Liabilities. Windlas Biotech's annualized ROCE % for the quarter that ended in Mar. 2026 was 14.76%.

Windlas Biotech  (NSE:WINDLAS) ROCE % Explanation

ROCE % can be especially useful when comparing the performance of capital-intensive companies. Unlike ROE %, which indicates the profitability of Shareholders Equity, ROCE % also considers long-term debt in Capital Employed. This can be helpful when analyzing companies with significant debt, as the result is neutralized by taking debt into consideration.

Generally speaking, a higher ROCE % indicates a stonger profitability for a company. Moreover, it is important to look at the ratio from a long term perspective. Investors tend to favor companies with stable and rising ROCE % trend over those with volatile ones.

Windlas Biotech ROCE % Related Terms

Windlas Biotech ROCE % Historical Data

* Premium members only.

The historical data trend for Windlas Biotech's ROCE % can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Windlas Biotech ROCE % Chart

Windlas Biotech Annual Data
Trend Mar19 Mar20 Mar21 Mar22 Mar23 Mar24 Mar25 Mar26
ROCE %
Get a 7-Day Free Trial 15.67 14.37 18.14 17.43 16.73

Windlas Biotech Quarterly Data
Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25 Mar26
ROCE % Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 17.34 19.03 18.19 15.71 14.76
NSE:WINDLAS
89GF Score
Windlas Biotech Ltd NSE:WINDLAS
ROCE % is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Windlas Biotech ROCE % Calculation

Windlas Biotech's annualized ROCE % for the fiscal year that ended in Mar. 2026 is calculated as:

ROCE %=EBIT/( (Capital Employed+Capital Employed)/ count )
(A: Mar. 2026 )  (A: Mar. 2025 )(A: Mar. 2026 )
=EBIT/( ( (Total Assets - Total Current Liabilities)+(Total Assets - Total Current Liabilities) )/ count )
(A: Mar. 2026 )  (A: Mar. 2025 )(A: Mar. 2026 )
=918.03/( ( (7604.5 - 2494.43) + (9073.48 - 3209.3) )/ 2 )
=918.03/( (5110.07+5864.18)/ 2 )
=918.03/5487.125
=16.73 %

Windlas Biotech's ROCE % of for the quarter that ended in Mar. 2026 is calculated as:

ROCE %=EBIT (1)/( (Capital Employed+Capital Employed)/ count )
(Q: Mar. 2026 )  (Q: Dec. 2025 )(Q: Mar. 2026 )
=EBIT/( ( (Total Assets - Total Current Liabilities)+(Total Assets - Total Current Liabilities) )/ count )
(Q: Mar. 2026 )  (Q: Dec. 2025 )(Q: Mar. 2026 )
=865.44/( ( (0 - 0) + (9073.48 - 3209.3) )/ 1 )
=865.44/( ( 0 + 5864.18 )/ 1 )
=865.44/5864.18
=14.76 %

(1) Note: The EBIT data used here is four times the quarterly (Mar. 2026) EBIT data.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Frequently Asked Questions Learn more about ROCE % →
What does a ROCE % of 14.76% mean?
Windlas Biotech (NSE:WINDLAS) has a ROCE % of 14.76% as of Mar. 2026.
Is Windlas Biotech's ROCE % too high?
Windlas Biotech's current ROCE % is 14.76%. The Drug Manufacturers industry median ROCE % is 7.00. Windlas Biotech's value of 14.76% is 111% above this industry median. Overall, Windlas Biotech has a GF Score™ of 89/100 and is considered Fairly Valued, reflecting its overall financial health beyond just this single metric.
How does Windlas Biotech's ROCE % compare to ZTS?
Windlas Biotech's ROCE % of 14.76% can be compared against companies in the Drug Manufacturers industry. The industry median ROCE % is 7.00. Windlas Biotech's value of 14.76% is 111% above this benchmark. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good ROCE % for a Drug Manufacturers company?
The median ROCE % among Drug Manufacturers companies is 7.00, based on 958 companies in the industry. Companies in the top quartile (top 25%) have a ROCE % significantly above this median, while those in the bottom quartile fall well below. However, ROCE % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Windlas Biotech's current ROCE % of 14.76% is 111% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high ROCE % mean?
A high ROCE % can signal that a stock is expensive relative to its fundamentals. For the Drug Manufacturers industry, the median ROCE % is 7.00 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Windlas Biotech's current ROCE % is 14.76%. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Windlas Biotech stock overvalued right now?
Based on GuruFocus' analysis, Windlas Biotech (NSE:WINDLAS) is currently considered Fairly Valued. The stock's GF Value™ is ₹936.76, compared to a current price of ₹863.80 — trading 7.8% below its estimated fair value. The current ROCE % is 14.76% and 111% above the Drug Manufacturers industry median of 7.00. Windlas Biotech's overall GF Score™ is 89/100 with 1 warning sign to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is ROCE % calculated?
ROCE % is calculated from a company's financial statements. For Windlas Biotech (NSE:WINDLAS), the current ROCE % is 14.76% as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is Windlas Biotech (NSE:WINDLAS) Overvalued in 2026?

Based on GuruFocus' analysis, Windlas Biotech stock appears to be undervalued. The current stock price of ₹863.80 is trading 7.8% below its estimated GF Value™ of ₹936.76. GuruFocus considers Windlas Biotech to be Fairly Valued.

Key valuation signals for NSE:WINDLAS:

  • ROCE %: 14.76%
  • GF Value™: ₹936.76 vs. price of ₹863.80 (7.8% below fair value)
  • GF Score™: 89/100 with 1 warning sign
  • Industry Position: 111% above the Drug Manufacturers median

No single metric tells the full story. See the NSE:WINDLAS stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.

Windlas Biotech Business Description

Other Exchanges 543329:India
Address Golf Course Extension Road, 705-706, Vatika Professional Point, Sector-66, Gurgaon, HR, IND, 122 001
Windlas Biotech Ltd is a pharmaceutical formulation contract development and manufacturing organization. The company offers a range of CDMO services from product discovery to product development, licensing, and commercial manufacturing of generic products including complex generics.
89GF Score

Get the complete analysis for NSE:WINDLAS

ROCE % is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

₹863.80
Price
₹936.76
GF Value